StreetInsider.com News Articles

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date

Context Therapeutics added to Russell 2000 and Russell 3000 indexes

Mon, 06 Jul 2026 16:07:36 -0400

Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, was added to the Russell 2000 and Russell 3000 indexes, effective at the close of U.S. equity markets on June 26, 2026, according to a company statement.

The Russell 3000 index tracks the largest 3,000 publicly traded U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell 2000 is a subset of the Russell 3000 and serves as a benchmark for U.S. small-cap equities.

Context Therapeutics is headquartered in Philadelphia and is developing T cell engaging bispecific antibodies for solid tumors.

Context Therapeutics added to Russell 2000 and Russell 3000 indexes

Mon, 06 Jul 2026 16:07:36 -0400

Context Therapeutics is headquartered in Philadelphia and is developing T cell engaging bispecific antibodies for solid tumors.

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Mon, 06 Jul 2026 16:07:00 -0400

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000® and the broad-market Russell 3000® Indexes, effective at the close of U.S. equity markets on June 26, 2026.

The Russell 3000® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell 2000® Index is a subset of the Russell 3000® Index and serves as the leading benchmark

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Mon, 06 Jul 2026 16:07:00 -0400

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Mon, 06 Jul 2026 16:07:00 -0400

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Mon, 06 Jul 2026 16:07:00 -0400

Form 4 Context Therapeutics For: Jun 24 Filed by: Pasternak Andy

Fri, 26 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260626/26699204.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Pasternak Andy

Fri, 26 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260626/26699204.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Stacey Jennifer Evans

Fri, 26 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260626/26699161.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Stacey Jennifer Evans

Fri, 26 Jun 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260626/26699161.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Smith Karen L.

Fri, 26 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26699135.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Smith Karen L.

Fri, 26 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26699135.html

Form 4 Context Therapeutics For: Jun 24 Filed by: West Linda

Fri, 26 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26699147.html

Form 4 Context Therapeutics For: Jun 24 Filed by: West Linda

Fri, 26 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260626/26699147.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Walker Luke Nathaniel

Fri, 26 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260626/26699119.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Walker Luke Nathaniel

Fri, 26 Jun 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260626/26699119.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Kantoff Philip W.

Fri, 26 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260626/26698848.html

Form 4 Context Therapeutics For: Jun 24 Filed by: Kantoff Philip W.

Fri, 26 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260626/26698848.html

Form 8-K Context Therapeutics For: Jun 24

Fri, 26 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260626/26698753.html

Form 8-K Context Therapeutics For: Jun 24

Fri, 26 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260626/26698753.html

Context Therapeutics (CNTX) PT Lowered to $4 at Maxim Group

Tue, 16 Jun 2026 09:55:15 -0400

Maxim Group analyst Jason McCarthy lowered the price target on Context Therapeutics (NASDAQ: CNTX) to $4.00 (from $8.00) while maintaining a Buy rating.